U.S. Electronic Equipment and Components Stock News

NasdaqGS:MCHP
NasdaqGS:MCHPSemiconductor

US Stock Market Today: S&P 500 Futures Dip amid Cooling Jobs, Mixed Soft-Landing Hopes

The Morning Bull - US Market Morning Update Thursday, Dec, 4 2025 US stock futures are slightly softer this morning, as investors juggle strong signals from the services side of the economy with a surprise cooling in hiring. A key health check on the services sector came in at 52.6 in November, showing businesses are still growing and prices are rising more slowly, which helps the case for steady growth without runaway inflation. But a separate jobs report showed private payrolls dropping by...
NasdaqGS:BDTX
NasdaqGS:BDTXBiotechs

Black Diamond Therapeutics (BDTX): Valuation Check After New Phase 2 Silevertinib Data and Glioblastoma Trial Plans

Black Diamond Therapeutics (BDTX) just released topline Phase 2 data for its EGFR inhibitor silevertinib in frontline non small cell lung cancer, while also laying out plans for a randomized Phase 2 trial in newly diagnosed glioblastoma. See our latest analysis for Black Diamond Therapeutics. The latest silevertinib update landed against a choppy backdrop for Black Diamond Therapeutics, with a sharp 1 day share price return of negative 22.03 percent and a 7 day share price return of negative...
NYSE:K
NYSE:KFood

Does Kellanova’s Snacks Focus Justify Its Strong Multi Year Share Price Gains?

Wondering if Kellanova is still fairly priced after its long run, or if there is more upside left in the tank? This breakdown will help you decide whether the current share price actually makes sense. The stock has been mostly treading water in the short term, down 0.6% over the last week and roughly flat over the past month at 0.1%. However, that hides a steadier climb of 2.6% year to date and 6.2% over the last year, compounding into 32.5% and 69.5% gains over the past 3 and 5...
NasdaqGM:TBPH
NasdaqGM:TBPHPharmaceuticals

Is Oppenheimer’s Focus on Ampreloxetine Quietly Redefining Theravance Biopharma’s (TBPH) Risk-Reward Profile?

Oppenheimer recently initiated coverage on Theravance Biopharma with an Outperform rating, emphasizing the importance of the Phase 3 ampreloxetine readout expected in the first quarter of 2026 and the company’s virtual key opinion leader event on this program. The focus on ampreloxetine as a potential billion-dollar therapy in a rare neurogenic condition highlights how pivotal this single late-stage asset has become for Theravance’s future prospects and risk profile. We’ll now explore how...
OTCPK:BHAT.F
OTCPK:BHAT.FEntertainment

Blue Hat Interactive (NasdaqCM:BHAT) Losses Persist, Reinforcing Bearish Narratives on Turnaround Prospects

Blue Hat Interactive Entertainment Technology (NasdaqCM:BHAT) has just posted its H1 2025 scorecard, with trailing twelve month revenue sitting at about $19.0 million and net income of roughly -$9.1 million, keeping EPS around $0 over that span. The company has seen revenue move from $27.4 million in H2 2023 to $18.7 million in H2 2024, while net income excluding extraordinary items shifted from -$22.3 million to -$8.2 million. The latest numbers still leave investors focused squarely on...
NasdaqGM:JANX
NasdaqGM:JANXBiotechs

Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed

Janux Therapeutics recently reported positive updated interim Phase 1 data for its PSMA-directed TRACTr candidate JANX007 in metastatic castration-resistant prostate cancer, based on 109 treated patients as of the October 15, 2025 cutoff, and held a virtual event on December 1 to discuss the results. The update highlights not only progress for JANX007 but also reinforces Janux’s broader TRACTr and ARM platforms, which span multiple solid tumors and an emerging CD19 program in autoimmune...